Literature DB >> 26941407

Understanding TERT Promoter Mutations: A Common Path to Immortality.

Robert J A Bell1, H Tomas Rube2, Ana Xavier-Magalhães3, Bruno M Costa4, Andrew Mancini1, Jun S Song5, Joseph F Costello6.   

Abstract

Telomerase (TERT) activation is a fundamental step in tumorigenesis. By maintaining telomere length, telomerase relieves a main barrier on cellular lifespan, enabling limitless proliferation driven by oncogenes. The recently discovered, highly recurrent mutations in the promoter of TERT are found in over 50 cancer types, and are the most common mutation in many cancers. Transcriptional activation of TERT, via promoter mutation or other mechanisms, is the rate-limiting step in production of active telomerase. Although TERT is expressed in stem cells, it is naturally silenced upon differentiation. Thus, the presence of TERT promoter mutations may shed light on whether a particular tumor arose from a stem cell or more differentiated cell type. It is becoming clear that TERT mutations occur early during cellular transformation, and activate the TERT promoter by recruiting transcription factors that do not normally regulate TERT gene expression. This review highlights the fundamental and widespread role of TERT promoter mutations in tumorigenesis, including recent progress on their mechanism of transcriptional activation. These somatic promoter mutations, along with germline variation in the TERT locus also appear to have significant value as biomarkers of patient outcome. Understanding the precise molecular mechanism of TERT activation by promoter mutation and germline variation may inspire novel cancer cell-specific targeted therapies for a large number of cancer patients. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26941407      PMCID: PMC4852159          DOI: 10.1158/1541-7786.MCR-16-0003

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  139 in total

1.  hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization.

Authors:  M Meyerson; C M Counter; E N Eaton; L W Ellisen; P Steiner; S D Caddle; L Ziaugra; R L Beijersbergen; M J Davidoff; Q Liu; S Bacchetti; D A Haber; R A Weinberg
Journal:  Cell       Date:  1997-08-22       Impact factor: 41.582

2.  Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.

Authors:  Dilek Cevik; Gokhan Yildiz; Mehmet Ozturk
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

3.  Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study.

Authors:  Pedro Castelo-Branco; Sanaa Choufani; Stephen Mack; Denis Gallagher; Cindy Zhang; Tatiana Lipman; Nataliya Zhukova; Erin J Walker; Dianna Martin; Diana Merino; Jonathan D Wasserman; Cynthia Elizabeth; Noa Alon; Libo Zhang; Volker Hovestadt; Marcel Kool; David T W Jones; Gelareh Zadeh; Sidney Croul; Cynthia Hawkins; Johann Hitzler; Jean C Y Wang; Sylvain Baruchel; Peter B Dirks; David Malkin; Stefan Pfister; Michael D Taylor; Rosanna Weksberg; Uri Tabori
Journal:  Lancet Oncol       Date:  2013-04-16       Impact factor: 41.316

4.  Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation.

Authors:  Hsien-Neng Huang; Ying-Cheng Chiang; Wen-Fang Cheng; Chi-An Chen; Ming-Chieh Lin; Kuan-Ting Kuo
Journal:  Mod Pathol       Date:  2014-08-01       Impact factor: 7.842

5.  Convergence of Ets- and notch-related structural motifs in a heteromeric DNA binding complex.

Authors:  C C Thompson; T A Brown; S L McKnight
Journal:  Science       Date:  1991-08-16       Impact factor: 47.728

6.  The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.

Authors:  T Liu; N Wang; J Cao; A Sofiadis; A Dinets; J Zedenius; C Larsson; D Xu
Journal:  Oncogene       Date:  2013-10-21       Impact factor: 9.867

7.  Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma.

Authors:  Glynis A Scott; Todd S Laughlin; Paul G Rothberg
Journal:  Mod Pathol       Date:  2013-09-13       Impact factor: 7.842

8.  Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers.

Authors:  Josh Lewis Stern; Dan Theodorescu; Bert Vogelstein; Nickolas Papadopoulos; Thomas R Cech
Journal:  Genes Dev       Date:  2015-10-29       Impact factor: 11.361

9.  TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.

Authors:  M Labussière; A L Di Stefano; V Gleize; B Boisselier; M Giry; S Mangesius; A Bruno; R Paterra; Y Marie; A Rahimian; G Finocchiaro; R S Houlston; K Hoang-Xuan; A Idbaih; J-Y Delattre; K Mokhtari; M Sanson
Journal:  Br J Cancer       Date:  2014-10-14       Impact factor: 7.640

10.  TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma.

Authors:  Klaus G Griewank; Rajmohan Murali; Bastian Schilling; Tobias Schimming; Inga Möller; Iris Moll; Marion Schwamborn; Antje Sucker; Lisa Zimmer; Dirk Schadendorf; Uwe Hillen
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

View more
  74 in total

1.  Discovery of New Fusion Transcripts in a Cohort of Pediatric Solid Cancers at Relapse and Relevance for Personalized Medicine.

Authors:  Célia Dupain; Anne C Harttrampf; Yannick Boursin; Manuel Lebeurrier; Windy Rondof; Guillaume Robert-Siegwald; Pierre Khoueiry; Birgit Geoerger; Liliane Massaad-Massade
Journal:  Mol Ther       Date:  2018-11-02       Impact factor: 11.454

2.  Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma.

Authors:  Jozefina Casuscelli; Maria F Becerra; Brandon J Manley; Emily C Zabor; Ed Reznik; Almedina Redzematovic; Maria E Arcila; Daniel M Tennenbaum; Mazyar Ghanaat; Mahyar Kashan; Christian G Stief; Maria Carlo; Martin H Voss; Darren R Feldman; Robert J Motzer; Yingbei Chen; Victor E Reuter; Jonathan A Coleman; Paul Russo; James J Hsieh; Abraham Ari Hakimi
Journal:  Eur Urol Focus       Date:  2017-09-24

Review 3.  The ETS family of oncogenic transcription factors in solid tumours.

Authors:  Gina M Sizemore; Jason R Pitarresi; Subhasree Balakrishnan; Michael C Ostrowski
Journal:  Nat Rev Cancer       Date:  2017-04-28       Impact factor: 60.716

Review 4.  TERRA Gene Expression in Gastric Cancer: Role of hTERT.

Authors:  Sogand Vahidi; Ali Akbar Samadani
Journal:  J Gastrointest Cancer       Date:  2021-01-07

5.  Development of Novel Mutation-Specific Droplet Digital PCR Assays Detecting TERT Promoter Mutations in Tumor and Plasma Samples.

Authors:  Broderick C Corless; Gregory A Chang; Samantha Cooper; Mahrukh M Syeda; Yongzhao Shao; Iman Osman; George Karlin-Neumann; David Polsky
Journal:  J Mol Diagn       Date:  2018-10-26       Impact factor: 5.568

6.  Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer.

Authors:  Marie Wong; Chelsea Mayoh; Loretta M S Lau; David S Ziegler; Paul G Ekert; Mark J Cowley; Dong-Anh Khuong-Quang; Mark Pinese; Amit Kumar; Paulette Barahona; Emilie E Wilkie; Patricia Sullivan; Rachel Bowen-James; Mustafa Syed; Iñigo Martincorena; Federico Abascal; Alexandra Sherstyuk; Noemi A Bolanos; Jonathan Baber; Peter Priestley; M Emmy M Dolman; Emmy D G Fleuren; Marie-Emilie Gauthier; Emily V A Mould; Velimir Gayevskiy; Andrew J Gifford; Dylan Grebert-Wade; Patrick A Strong; Elodie Manouvrier; Meera Warby; David M Thomas; Judy Kirk; Katherine Tucker; Tracey O'Brien; Frank Alvaro; Geoffry B McCowage; Luciano Dalla-Pozza; Nicholas G Gottardo; Heather Tapp; Paul Wood; Seong-Lin Khaw; Jordan R Hansford; Andrew S Moore; Murray D Norris; Toby N Trahair; Richard B Lock; Vanessa Tyrrell; Michelle Haber; Glenn M Marshall
Journal:  Nat Med       Date:  2020-10-05       Impact factor: 53.440

Review 7.  Finding cancer driver mutations in the era of big data research.

Authors:  Rebecca C Poulos; Jason W H Wong
Journal:  Biophys Rev       Date:  2018-04-02

8.  Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy.

Authors:  Hyunseok Kang; Dean Pettinga; Adrian D Schubert; Paul W Ladenson; Douglas W Ball; Jon H Chung; Alexa B Schrock; Russell Madison; Garrett M Frampton; Phil J Stephens; Jeffrey S Ross; Vincent A Miller; Siraj M Ali
Journal:  Oncologist       Date:  2018-10-29

Review 9.  Non-coding driver mutations in human cancer.

Authors:  Kerryn Elliott; Erik Larsson
Journal:  Nat Rev Cancer       Date:  2021-07-06       Impact factor: 60.716

10.  Disruption of the β1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner.

Authors:  Andrew Mancini; Ana Xavier-Magalhães; Wendy S Woods; Kien-Thiet Nguyen; Alexandra M Amen; Josie L Hayes; Christof Fellmann; Michael Gapinske; Andrew M McKinney; Chibo Hong; Lindsey E Jones; Kyle M Walsh; Robert J A Bell; Jennifer A Doudna; Bruno M Costa; Jun S Song; Pablo Perez-Pinera; Joseph F Costello
Journal:  Cancer Cell       Date:  2018-09-10       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.